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1. Introduction 
Epilepsy is a complex issue that has an impact on the 
patients’ quality of life. Treating epilepsy means a life-time 
treatment, so real-life studies are important. Camfield concluded 
that population-based research with large grouping had a 
considerable impact on the understanding of epilepsy. Many 
factors, including comorbidities and their medication, could 
influence the outcome of antiepileptic treatment. A number of 
drugs can predict patient adherence. ADRs are commonly 
experienced with antiepileptic drug (AED) treatment. Most of the 
ADRs are mild and tolerable, but severe effects have also been 
reported. Due to long duration of treatment, various ADRs are seen, 
which requires change of medication and monitoring. 
The prevalence of ADRs is described using Proportional 
Reporting Ratio (PRR) and Reported Odds Ratio (ROR) beside 
basic characteristics. PRR means the portion of spontaneous report 
for a specified drug with certain ADR divided by the corresponding 
proportion of other drugs or group of drugs. PRR can be used as a 
direct measure of the strength of the signal and it can also be used 
to determine unexpectedness relative to the background of the rest 
of the database. ROR provides additional information over PRR, 
which can be important in evaluating the link between ADRs and 
drugs. Furthermore, ROR allows the estimation of relative risk and 
removal of biases. Using PRR and ROR, signal of disproportionate 
reporting (SDR) can show the association between drug-event pair 
in the database which can be generated from spontaneous adverse 
drug reaction reporting systems based on European Medicines 
Agency (EMA) criteria. 
In 1996, the World Health Organization (WHO) launched 
the methodology defining the daily dose (DDD), a widely used tool 
in drug utilization studies. Although DDD is an average 
maintenance dose in adults by definition and a unit used in drug 
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consumption, notwithstanding, contradictions with prescribed 
daily dose (PDD) can be observed. 
Studies have confirmed that combination therapy is used in 
the minority of cases; notably, the proportion of combination 
therapy reported in four studies by Brodie et al., Kořístková et al. 
and Rochat et al. fell in the range of 15-38.2%. Accordingly, there 
is another contradiction between clinical practice and DDDs of 
AEDs assigned for combination therapy in the case of AEDs by 
WHO. 
DDD is used not only as a simple number to compare 
different periods and/or regions, it is used, e.g., for the estimation 
of ever-users’ prevalence in the equation of population attributable 
risk (PAR). Further importance of the DDD has been published by 
Kwan et al. and Brodie et al. who concluded that effective seizure 
control could be achieved at 50% or 75% of DDD and could be 
applied to the definition of drug-resistant epilepsy. 
2. Aim of the study 
East-Hungarian Epilepsy Database was created in order to 
analyse the data of patients through their case histories from out-
patient files, covering the period between 1992 and 2011 in a cross-
sectional view. 
Our aims were the following: 
1. It was our intention to find out what factors might influence 
PDD. 
2. What kind of correlation is between PDD and DDD in 
case of seizure freedom? 
3. We wanted to test the applicability of 75% cut-off of DDD 
to achieve seizure freedom. 
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4. Is there any effect of the concomitant medication acting on 
the central nervous system (CNS) on the outcome of 
epilepsy treatment? 
5. Is the ADR of newer type AEDs favourable than the 
older type ones? 
3. Methods 
In our database we registered all of the adult patients (2152) 
who were referred to our out-patient or in-patient department by 
general practitioners or other out-patient clinics. Our epilepsy out-
patient unit provides care for patients from 16 years of age. 
We excluded those who had no seizures at all or their 
seizures were related to alcohol dependency. 
Eventually, 1528 patients with epileptic seizures were 
included in the database. Patients were coded with epilepsy 
diagnoses in accordance with the International Classification of 
Diseases by the World Health Organization. 
Data were obtained from every patient at the first and 
subsequent out-patient visits, also from past medical records as 
well as family members. We collected 60 parameters per patient. 
Among others, data were entered into the database as follows: 
 gender, age at the first visit, age at the onset of 
epilepsy,  
 family history of epilepsy, risk factors of epilepsy 
(including febrile convulsions),  
 relevant details of past medical and neurological 
history such as congenital disorder, type of 
delivery, miscarriage, causes of symptomatic 
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epilepsy, neurological and psychiatric 
comorbidities,  
 influence of meteorological factors, classification 
of present and past seizures, frequency of each 
seizure type,  
 EEG and imaging findings,  
 past and present antiepileptic drug treatment, 
further drugs acting on the CNS, ADR and drug 
interactions, etc. 
Concomitant drugs acting on the CNS were prescribed by 
a neurologist / epileptologist, psychiatrist or general practitioner. 
All the patients with potential drug or alcohol-induced, 
psychogenic and heart-related seizures were excluded. The patients 
were classified as suffering from generalized, focal and unknown 
seizures according to the ILAE definition. 
Recurring seizures were observed in 1372 (89.8%) patients 
so, in accordance with the ILEA definition, these patients had 
epilepsy, and 156 (10.2%) patients had provoked and/or metabolic 
failure-induced seizures. 
The data of 1282 patients who had taken AEDs were 
retrieved from the database and analysed on the basis of gender, 
age, age at seizure onset, seizure type (generalized and focal), 
seizure freedom status as an outcome of treatment, and PDD. PDD 
was calculated on the basis of the proposed dosage regimen of the 
last follow-up visit. For each patient, DDD% was computed as the 
percentage of PDD divided by DDD and mean DDD% was 
calculated in order to compare different groups. The 75% cut-off 
have been chosen based on Brodie et al.’s suggestion. 
The relationship of PDD to DDD was analysed in 894, 286 
and 102 epileptic patients on monotherapy, bitherapy and 
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polytherapy, respectively. The most commonly used AEDs and 
their role in the outcome of these groups were compared. 
The epileptologists chose the best treatment modality for 
each patient. In most cases the first two AEDs were prescribed as 
monotherapy. If monotherapy had failed a combination was 
considered. Doses were built up very carefully in accordance with 
the summary of product characteristics (SPC) up to a medium dose 
range, and were further increased up to the maximally tolerated 
dose in case seizures occurred repeatedly. 
According to ILAE definition seizure freedom meant at 
least three times the interval of the longest previous interseizure 
duration (determined from seizures occurring within the past 12 
months, or in any 12-month-period, whichever was longer). We 
followed up the patients’ status for many years (until closing the 
database), to determine whether their seizures truly came under 
control. 
The seizure freedom and current therapy were determined 
at the last follow-up visit. 
On the basis of the above, our database stores individual 
case safety reports (ICSRs). 
We used the criteria of EMA for generating a signal. 
Statistics 
Statistical analysis was carried out using the SPSS for 
Windows 19.0 (SPSS Inc. Chicago, USA) and Microsoft Office 
Excel 2007. 
Two-sample T test, and F test were used to analyse our 
patients’ data. Categorical variables were assessed using Pearson 
χ2 test. 
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As per standard pharmacovigilance practices, the values of 
the PRR and ROR were computed using 2x2 contingency table. 
We used logistic regression model in order to analyse what 
kind of factors influenced seizure freedom, where seizure freedom 
was the dependent variable and gender, age group, type of seizure, 
other drugs acting on the CNS, number of AEDs and ADR were 
the independent variables. 
Another logistic regression model was created in order to 
analyse what factors characterised 75% DDD cut-off; the 
dependent variable was equal to or less than 75% of DDD and more 
than 75% of DDD. The independent variables included gender, age 
group, age at the onset of seizure, type of seizure, seizure freedom, 
other CNS related drugs and number of AEDs. 
Significant differences were considered if p<0.05. 
4. Results 
4.1. Basic characteristics of patients 
Mean age of all registered patients was 48.28 ±18.18 years 
with no significant difference (male: 49.25±17.9, female: 
47.33±18.42 years). 
The mean duration from the first epileptic seizure was 9.54 
years despite the fact that 686 patients were diagnosed with new 
onset epilepsy during the 20 years’ study period. 
Eight hundred and fifty-six (56%) of the patients had 
generalized seizures, 602 (39.4%) had focal seizures (no significant 
difference in gender between seizure type v. all patients; p= 0.20 
and p= 0.27 respectively) and 70 (4.6%) of the patients had 
unknown seizures. Gender ratios (male/female) were 1.09 in the 
generalized seizure group and 0.88 in focal seizure group (gender 
was significantly different, p=0.04). 
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Family history was positive for epilepsy in 107 (7.8%) out 
of 1372 patients. Idiopathic epilepsy affected 228 (16.6%) patients 
whereas symptomatic epilepsy was confirmed in 574 (41.8%) 
patients (stroke: 185 [32.2%], head injury: 155 [27%], congenital 
disorders: 76 [13.2%], tumour: 74 [12.9%], CNS infection: 57 
[9.9%], other disorders such as cerebral atrophy or arachnoid cyst: 
27 [4.7%]). Cryptogenic epilepsy and new onset epilepsy were 
diagnosed in 570 (41.2%) and 686 (50%) patients, respectively. 
4.2. Treatment characteristics 
Among the recruited patients, 1282 (93.4%) took AEDs but 
90 (6.6%) did not due to 5-10 years of seizure free status. 
The mean number of AEDs per patient was 1.4. 
According to the last follow-up visit 894 (70%) of the 
patients were on monotherapy, 286 (22%) on bitherapy and 102 
(8%) on polytherapy. Being on monotherapy, the majority of 
patients took CBZ, VPA and LTG (449 [50.2%], 197 [22%] and 
118 [13.2%], respectively). PHT and phenobarbital (PB) 
prescriptions amounted to only 11 (1.2%) and 4 (0.4%) 
respectively. Newer AEDs were taken by 229 patients (25.6%); 
(LTG; 118 [13.2%], OXC; 61 patients [6.8%]) and LEV; 35 
patients [3.9%]) were the most commonly prescribed ones in this 
group. 
Among the patients on monotherapy (N=894), 464 patients 
(52%) took AEDs which had an enzyme-inducing effect on drug 
metabolizing enzymes (CYPs systems), 197 patients (22%) were 
prescribed with enzyme inhibiting AEDs, 62 patients (7%) used 
AEDs with both effects on enzyme systems and in 171 patients 
(19%) the AED had no effect on liver metabolizing systems. 
Bitherapy included 15 AEDs prescribed in 45 different 
combinations. 
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Old-old, old-new and new-new AED combinations were 
prescribed for 118 (41%), 133 (47%) and 35 (12%) patients, 
respectively. The prevalence of newer AEDs use was 35.5%. As 
for the number of participants, there was no significant difference 
between males and females on mono-, bi-, or polytherapy. 
The enzyme inhibitor (only VPA) played the same role in 
mono-, bi-, and polytherapy (197 [22%], 122 [21.3%], and 65 
[19.4%], respectively). In both groups on bi- and polytherapy, the 
second choice of AEDs was for an enzyme inducer and/or inhibitor. 
Seizure freedom was achieved in 47% of all treated 
patients. The overall seizure freedom was 693 (50.5%) including 
those patients (90, 6.6%) who did not take AEDs because of long-
term seizure freedom. We calculated seizure freedoms in patients 
with generalized and partial epilepsy, 396 (52.1%) and 283 
(49.8%), respectively. Seizure freedom was 48 (45.5%) among the 
patients with positive family history of epilepsy. In the subgroup 
idiopathic, symptomatic, cryptogenic and new onset epilepsy 
seizure freedom was 125 (55%), 258 (45%), 288 (50.5%) and 340 
(49.5%) respectively. Differences were not significant. Among the 
seizure free patients 77% of the patients were given monotherapy, 
19% received bitherapy and only 4% were on polytherapy. 
In the logistic regression model, the number of AEDs and 
other drugs acting on the CNS had a significant impact on seizure 
freedom. 
Non-adherence was associated with 154 (12%) patients. 
4.3. Correlation between prescribed daily dose, seizure freedom 
and defined daily dose 
Comparing the number of prescribed old and new AEDs, a 
significant increase was observed in the proportion of newer AEDs 
between the mono- versus bitherapy (p<0.0001) and bi- versus 
polytherapy groups (p=0.0003). 
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The mean DDD% of all prescribed AEDs increased 
steadily from monotherapy, through bitherapy towards polytherapy 
(58.54%±24.04, 74.38%±42.89, 93.68%±54.82, respectively). 
CBZ and OXC showed similar patterns but CBZ was 
prescribed in less than 75% of DDD, while OXC was prescribed in 
all scenarios in more than 75% of DDD. 
In the case of VPA, mono- and bitherapy PDDs remained 
below 75% of DDD but in the group on polytherapy a higher dose 
did not increase the likelihood of seizure freedom. 
Monotherapy 
Mean PDDs mostly fell in the range between 50-75% of 
DDDs. 
With the exception of OXC and GBP, the mean DDD% was 
higher in the group of not seizure free patients. Except for OXC, 
the vast majority of seizure free patients had taken AED doses in 
the range of ≤75% of DDDs in monotherapy. Not seizure free 
patients were treated with higher doses of LTG, and significant 
differences in means could be seen between seizure free and not 
seizure free cohorts (p=0.02). 
The mean DDD percentage was equal to or less than 75% 
in most AEDs used in monotherapy in the group of seizure free 
patients. A significant difference was revealed only among LTG 
users (p=0.032) in favour of ≤75% of DDD and seizure free 
patient’s group. The mean DDD% exceeded 75% in four cases as 
follows: clobazam (CLB), OXC, topiramate (TPM) and lacosamide 
(LCM), 100%, 86.82%, 133.3% and 133.3%, respectively. No 
preferable AED was confirmed based on general effectiveness 
(p=0.65) in relation to desired seizure free status. 
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Bitherapy 
The mean PDDs of CBZ, VPA, PRM, CLZ, GBP and VGB 
were within 50-75% of DDD. 
Significantly higher mean DDD% was observed between 
seizure free and not seizure free cohorts taking LEV; p=0.023). 
Slightly higher mean DDD% was revealed among seizure free 
patients on CLB and PRM. 
The majority of patients belonged to the group of equal to 
or less than 75% of DDD (except CLB, OXC, PHT). 
Polytherapy 
Only PDDs of CBZ, PHT, PRM and CLZ remained under 
75% of DDD. 
The mean DDD% was higher among not seizure free 
patients but no significance was confirmed (except CBZ p=0.032 
and GBP p=0.045; not seizure free patients taking LEV and TPM 
had lower values but the differences were not significant). 
In polytherapy, the use of more than 75% of DDDs was 
recorded in the seizure free and not seizure free groups receiving 
LEV, LTG, OXC and TPM. The mean DDD% was higher among 
TPM, PRM and LEV users in the seizure free group. 
Among the older types of AEDs, both CBZ and VPA had 
to be given in a significantly higher mean dose in bitherapy than in 
monotherapy in the seizure free group and in polytherapy in the not 
seizure free group. Among the newer types, only LEV and LTG 
had a significantly higher DDD% series pattern between mono-, bi-
, and polytherapy in both groups (except LEV in polytherapy in the 
not seizure free) group. 
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The mean DDD% of CBZ and GBP in polytherapy was 
significantly higher in not seizure free patients than in the seizure 
free group (p=0.032 and 0.045, respectively). 
Logistic regression analysis 
In this model, gender, age group, type of seizure, seizure 
freedom and number of AEDs all had a significant impact (all 
p<0.05). 
In the logistic regression model, gender served as a 
significant predictor (p=0.001; Exp(B) [exponentiation of the B 
coefficient]= 1.456, 95% CI [Confidence Interval]: 1.169-1.813) if 
it was equal to or less than 75% of DDD among men. 
Current age showed significant difference in the model of 
≥75% of DDD in the over 65-year-old group (p=0.022; Exp(B)= 
1.449, 95% CI: 1.055-1.989). 
The odds were higher for focal seizures in more than 75% 
of DDD group (p=0.002; Exp(B)= 0707, 95% CI: 0.568-0.881) and 
equal to or less than 75% of DDD in generalized seizure. 
There was no higher chance for seizure freedom if more 
than 75% of DDD was prescribed (p= 0.027, Exp(B)= 0.773, 95% 
CI: 0.616-0.971). 
As a result of increasing the number of AEDs, a higher 
portion of more than 75% of DDD could be achieved in the logistic 
regression model. 
4.4. Concomitant drugs acting on the CNS 
Two hundred and seventy-nine (22%) patients took 
concomitant drug(s) acting on the CNS. Although no gender-based 
difference was established within the “monotherapy” group 
concerning patients with or without seizures, significant 
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differences were confirmed regarding either one (p= 0.03) or ≥2 
(p= 0.03) certain other medicines acting on the CNS. Comparing 
the number of patients with or without CNS co-medication the 
difference was even more pronounced (p=0.003). 
There was a significant difference between all seizure free 
and all seizure-affected patients on AEDs taking two or more drugs 
acting on the CNS (p= 0.02). 
Analysing and comparing all the patients who took at least 
one type of medicine acting on the CNS with the ones that did not, 
we found the difference was significant (p=0.009). 
Only 22 (8%) of the 279 patients were on psychoactive 
drugs which could alter the effects of AEDs; CBZ, LTG, PHT and 
VPA being the AEDs in the focus of attention. 
4.5. Adverse drug reaction (ADR) 
Patients on AED monotherapy exhibited fewer ADRs than 
the patients on bi- or polytherapy. The differences between males 
and females were significant in the monotherapy group (p=0.003). 
There was an unfavourable but not significant trend in the 
occurrence of ADRs among female patients on bitherapy. 
Of 1528 ADRs (incidence: 16.2%) were reported by 247 
patients (male: 89 [36%], female: 158 [64%]). The vast majority 
(195; 80%) of the patients had one ADR and while 52 (20%) 
suffered two or more ADRs. The majority of patients with ADR 
were female. The differences were significant (1 ADR p= 0.008; 2 
ADRs p= 0.009). Among those having ADRs, the number of 
seizure free patients and those with recurrent seizures were not 
significantly different. 
Altogether 423 ADRs were reported due to 326 AEDs by 
our 247 patients. Most of them were women (217, 66.6%) reports 
from women and 109 (33.3%) from men. 
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In the pharmacovigilance report, all the patients having 
ever taken a certain AED according to out-patient files were 
included in the report. Surprisingly, newer AEDs (except LEV) 
showed higher values of PRR and ROR. 
Comparing PRR and 95% CI of old (PRR: 0.86; 95% CI 
[0.67-1.05], χ2= 2.42, p=0.12) and new (PRR: 1.16; 95% CI [0.97-
1.35], χ2= 2.42, p=0.12) generation AEDs, we found no significant 
superiority of newer AEDs in accordance with the EMA criteria. 
5. Discussion 
5.1. Basic characteristics of patients 
There was not a second peak in the incidence of new onset 
seizures over 50 years of age, although, in adults, stroke was the 
most common cause of symptomatic epilepsy, which is quite 
common in this age group. 
In our database, the ratio of generalised epilepsy was higher 
than in the adult epileptic population with newly diagnosed 
epilepsy, but we registered and attended patients with idiopathic 
generalised epilepsy too after 16 years of age. 
Stroke and head injury followed by congenital disorders 
were the most common causes of symptomatic epilepsy. The great 
majority of these patients had focal seizures which evolved into 
bilateral convulsive seizures. 
Mortality rate was 6.9% primarily because of 
comorbidities. 
5.2. Treatment characteristics 
In contrast with certain data in the literature, PHT and PB 
prescriptions were quite uncommon. Newer AEDs (taken by 25.6% 
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of patients) were indicated frequently in both monotherapy and 
bitherapy. 
One probable explanation for these differences in the 
literature might be that our epilepsy out-patient unit provides care 
for patients from the age of 16 and our female patients were 
potentially in adolescent or childbearing age which was also taken 
into consideration. The severe side effects of VPA, PHT and PB 
have been widely known. Another explanation for differences in 
the literature and our findings might be that some patients have 
comorbidities at the onset of epilepsy and there are a number of 
newly evolving disorders requiring a switch to a non–enzyme-
inducing AED (e.g. cancer therapy, osteoporosis, hyperlipidemia, 
sexual dysfunction and infertility). 
A recent study reported 68% overall seizure freedom in 
generalized and partial seizure which was higher than our finding 
(50.5%). We did not find significant difference between patient 
groups with generalized and partial epilepsy (p=0.41). 
More than 30% of patients were given two or more AEDs. 
In our database, 35.8% of these patients were seizure free, which is 
higher than the figure (20.5%) in a study by Stephen LJ et al. 
In our database, VPA, an enzyme inhibitor, played the same 
role in mono-, bi-, and polytherapy. Almost one in five patients 
took an AED without enzymatic effect in the monotherapy group. 
In both of the bi-, and polytherapy groups, the second choice of 
AEDs was for enzyme inducers or inhibitors. Nowadays, in routine 
clinical practice first line AEDs should be used depending on the 
type of epilepsy but prior to prescribing of enzyme inducer AED, 
physicians should always consider interactions with co-
medications (e.g. antidepressants, antipsychotics, cytostatics, 
antiretrovirals, statins, anticoagulants, oral contraceptives, 
immunosuppressant, analgesics, antihypertensives, etc.). 
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Our data may confirm Brodie’s opinion that physicians 
should consider starting treatment with, or even switching patients 
to non–enzyme-inducing AEDs in order to avoid complications, 
particularly if the epilepsy is not fully controlled. 
In our database, non-adherence to treatment in patients with 
epilepsy was better (12%) than in the report by Jones et al. in a 
cross-sectional study (59%) but we did not use special 
questionnaire scores comparing the patients with well and poorly 
controlled epilepsy. 
5.3. Correlation between prescribed daily dose, seizure freedom 
and defined daily dose 
The treatment of epileptic patients is complex. Of course, 
there are conditions (drug interactions, individual differences in 
drug metabolism, age, comorbidities, etc.) that emphasise the 
importance of individual treatment in finding the proper dosage of 
AED. However, evidence including DDD, clinical trials or TDM is 
important when choosing the best AED treatment for the patient. 
In our study, a new, clinically important, well-defined and 
feasible approach was tried in order to determine the correlation 
between PDD and PDD/DDD ratios based on seizure freedom as 
an outcome of AED treatment. One of our goals was to see whether 
PDD/DDD could play a role in seizure freedom as an outcome 
measure in epilepsy; no significant unfavourable impact of the 
lower ratio of PDD/DDD on the outcome of achieving seizure 
freedom could be confirmed. 
According to our data and similar to publications by others, 
AEDs – including more newer type ones – are prescribed in 
monotherapy for more and more patients, but while DDDs of AEDs 
refer to combination therapy. Therefore, references of 
monotherapy DDD values are needed for appropriate calculation. 
The more precisely DDD is quantified the more accurate 
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calculation of other derived values (e.g. DDD/1000 
inhabitants/day, prevalence of drug use, population attributable 
risk) it would provide, which could also play an important role in 
decision-making in health care. 
A significant increase was observed in the proportion of 
newer AEDs in our database. Probably these data were obtained 
with due consideration to the different modes of action of AEDs 
and their favourable ADRs in bitherapy and polytherapy. 
In our outpatient setting, the mean PDDs of AEDs were 
inconsistent with the DDD. Previous investigations were of the 
same opinion. 
The mean DDD% was equal to or less than 75% for the 
most commonly prescribed AEDs used in monotherapy in the 
seizure free group. In contrast with our findings, Hsieh and Huang 
did not reveal more than 100% of DDD. One of the explanations 
might be that older AEDs were prescribed more circumspectly due 
to their well-known ADRs. At the same time, the ADR profiles of 
new AEDs were considered more beneficial. In case of two newer 
types of AEDs (LTG and LEV) a significant rise in doses between 
mono-, bi-, and polytherapy was detected, by other AEDs a wide 
variety of mean DDD% supposes individual treatment regimen. 
Still CBZ and VPA are widely prescribed in the clinical practice 
due to reliable effectiveness and their broad-spectrum. These drugs 
can be used in low and moderate doses, too. 
Our findings suggested that doses equal to or less than 75% 
of DDD in monotherapy were effective in seizure control and the 
same quantities were confirmed in bi-, and polytherapy. However, 
a higher DDD% did not guarantee seizure freedom which 
emphasises the importance of individual therapy. 
It must be remarked that despite the low case numbers of 
some AEDs (e.g. CLB, CZP, PRM, STM, LCM and TPM) which 
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were statistically unfit for analysis the majority of the patients on 
these agents were seizure free. These findings highlighted the 
importance of carefully choosing drugs carefully, i.e. tailored to the 
individual e.g. in the treatment of special epileptic syndromes. 
Prescribing newer AEDs in bitherapy drug combinations 
has become an established practice now. This research has revealed 
the spread of newer type AEDs in epilepsy treatment but they are 
used not only in combinations, but also in monotherapy among 
patients on AEDs. The findings of this study suggest that individual 
therapy in epilepsy must be emphasised but 75% of DDD may also 
be used as a measure in case of seizure freedom. New-new 
combinations were given to 38 (12.2%) patients on bitherapy and 
133 (46.5%) patients took old-new combinations. In choosing the 
second and third AEDs it may have played an important role 
whether or not the specific AED had an enzyme-inducing or 
enzyme-inhibiting effect on the liver’s enzyme system. 
A statistically significant, higher DDD% was confirmed 
between seizure free and not seizure free groups only when LEV 
was administered. 
With logistic regression analysis, gender, age, type of 
epilepsy and the number of AEDs were found to have had a 
significant impact on the value of 75% DDD. These were the 
factors what influenced PDD. These might be limiting factors when 
making conclusions in studies using DDD. 
The present study confirmed that the DDD of prescribed 
AEDs was equal to or less than 75% of DDD instead of being over 
75% among elderly patients. It was in accordance with well-known 
pharmacokinetic and pharmacodynamic changes in older ages and 
due to comorbidities and co-medications. 
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It must be mentioned that, similarly to Kwan et al. and 
Brodie et al., our findings also emphasise individual therapy and 
the importance of 75% of DDD. 
5.4. Concomitant drugs acting on the CNS 
Psychiatric comorbidities are not infrequent in patients with 
epilepsy. Use of antidepressant and antipsychotic drugs is common 
in patients receiving enzyme-inducing AEDs. We analysed and 
compared all the patients who took at least one medicine acting on 
the CNS with those who did not; there was a significant difference 
between the two groups. 
In our logistic regression model, we found that the number 
of AEDs and other drugs acting on the CNS affected seizure 
freedom and had a significant impact. Increase in the number of 
AEDs and the presence of other drugs acting on the CNS reduced 
the chance of seizure freedom significantly. 
The explanation of these results may be that these 
interactions are very complex and combine pharmacokinetic and 
pharmacodynamic processes. Although variations in the extent of 
induction may differ between CYPs, there must be common 
cellular signalling mechanisms, nuclear receptors (glucocorticoid 
and oestrogen) may also participate in the induction of certain 
drugs; however, the transcription factors appear to be broadly 
involved in enzyme induction. 
AED doses were built up very carefully, probably that is 
why our patients had relatively fewer ADRs and interactions 
between AED(s) and concomitant drugs acting on the CNS. 
In clinical studies, researchers have demonstrated that the 
magnitude of induction of various CYP isoenzymes appears to be 
at least partially dependent upon the dose of the enzyme-inducing 
drug. 
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5.5. Adverse drug reaction (ADR) and pharmacovigilance 
evaluation of AEDs 
Chronic use of AEDs may be associated with several 
adverse events with systemic effect and affecting the CNS. 
Furthermore, enzyme-inducing AEDs may contribute to the 
development of comorbidities. Modern AEDs that lack this 
property have similar efficacy in common epilepsies. Quality of life 
and adherence to treatment depend on seizure control and the 
presence of ADRs. 
The incidence of self-reported ADRs was 16.2%, 
approximately half as much (36.5%) as the incidence rate in an 
Italian study; these patients had drug-refractory epilepsy and only 
less than a quarter of them received monotherapy. We found that 
women reported ADRs more frequently than men did. It was 
especially unexpected among patients on monotherapy; the 
difference was significant. Female dominance (64%) concerning 
ADR rates could be attributed to genetic polymorphism. 
In the database, we found that most of the patients were on 
older AEDs such as CBZ, VPA and PHT, and on LTG, LEV and 
OXC belong to newer AEDs. Although newer AEDs were 
considered more beneficial owing to the fewer ADRs they caused; 
except for LEV, our data suggested the same profile as that of the 
older ones. 
The results of PRR analysis of older versus newer AEDs 
with ADR were unexpected, they revealed no significant 
superiority of newer AEDs. The underlying cause of overreported 
ADRs regarding newer AEDs may have been associated with 
greater awareness to the newly marketed drugs and these drugs 
were introduced as add-on therapy. If a newly introduced drug was 
prescribed, patients’ education was much more thorough and the 
new drug was strictly monitored. 
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Using PRR and χ2, SDR showed the association between 
drug-event pairs in the database. No unknown or new ADR was 
detected in our database. Only eight ADRs fulfilled the EMA 
criteria to report signal detection. Three out of eight were newer 
AEDs. Due to the relatively low number of cases, only the most 
common symptoms met the definition of SDR. 
New establishments 
1. Using logistic regression model, gender, age, type of epilepsy 
and number of AED had a significant impact on PDD. 
2. The mean PDDs of AEDs were inconsistent with the DDD. 
No significant inferiority of the lower ratio of PDD/DDD in 
the outcome of achieving seizure freedom has been confirmed 
and a higher DDD% did not guarantee seizure freedom. 
3. The findings of this study suggest that 75% of DDD may be 
used as a measure of seizure freedom, but individual therapy 
in epilepsy must be emphasised. 
4. Concomitant drug acting on the CNS influenced seizure 
freedom unfavourably. 
5. The results of PRR analysis of older versus newer AEDs 
with ADR were unexpected; they revealed no significant 
superiority of newer AEDs. 
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